Literature DB >> 19896635

Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial.

Michele Reibaldi1, Nicola Cardascia, Antonio Longo, Claudio Furino, Teresio Avitabile, Salvatore Faro, Marisa Sanfilippo, Andrea Russo, Maurizio Giacinto Uva, Ferdinando Munno, Vincenzo Cannemi, Marco Zagari, Francesco Boscia.   

Abstract

PURPOSE: To evaluate the efficacy of low-fluence compared with standard-fluence rate photodynamic therapy (PDT) for treating chronic central serous chorioretinopathy.
DESIGN: Prospective, multicenter, investigator-masked, nonrandomized clinical trial.
METHODS: Forty-two eyes (42 patients) with chronic central serous chorioretinopathy were enrolled; 19 eyes received indocyanine green angiography-guided standard-fluence PDT (50 J/cm(2)) and 23 eyes received indocyanine green angiography-guided low-fluence PDT (25 J/cm(2)). Primary outcome measures were the changes in mean logarithm of the minimal angle of resolution best-corrected visual acuity and the rate of eyes with complete subretinal fluid reabsorption. Secondary outcomes were the changes in central foveal thickness and choroidal perfusion.
RESULTS: Mean logarithm of the minimal angle of resolution best-corrected visual acuity improved significantly at all time points (P < .01), in the standard-fluence group from 0.43 to 0.24 at 12 months and in the low-fluence-group from 0.46 to 0.16, without significant difference between the 2 groups. At 12 months, a complete subretinal fluid reabsorption was seen in 15 standard-fluence-treated and 21 low-fluence-treated eyes (79% vs 91%; P = .5). In 1 standard-fluence eye, choroidal neovascularization developed at 3 months, and this eye received further PDT; in the other eyes, at 12 months, a moderate-significant choriocapillaris nonperfusion was seen in 8 standard-fluence-treated and 0 low-fluence-treated eyes (44% vs 0%; P = .002).
CONCLUSIONS: In most of the eyes, both standard-fluence PDT and low-fluence PDT resulted in complete subretinal fluid reabsorption with visual acuity improvement. Choroidal hypoperfusion related to PDT could be reduced by low-fluence PDT. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19896635     DOI: 10.1016/j.ajo.2009.08.026

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  66 in total

1.  Finasteride for chronic central serous chorioretinopathy.

Authors:  Farzin Forooghian; Annal D Meleth; Catherine Cukras; Emily Y Chew; Wai T Wong; Catherine B Meyerle
Journal:  Retina       Date:  2011-04       Impact factor: 4.256

2.  Combined photodynamic therapy with verteporfin and intravitreal anti-vascular endothelial growth factor therapy for chronic central serous chorioretinopathy.

Authors:  J Fernando Arevalo; Juan V Espinoza
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-12-06       Impact factor: 3.117

3.  [Experiences with chronic central serous chorioretinopathy treated with half-dose photodynamic therapy and verteporfin].

Authors:  M Töteberg-Harms; M Kurz-Levin; J Fleischhauer; R Windisch
Journal:  Ophthalmologe       Date:  2011-10       Impact factor: 1.059

4.  Visual outcomes and anatomic changes after sub-threshold micropulse yellow laser (577-nm) treatment for chronic central serous chorioretinopathy: long-term follow-up.

Authors:  A Arsan; H S Kanar; A Sonmez
Journal:  Eye (Lond)       Date:  2018-01-05       Impact factor: 3.775

5.  Finasteride is effective for the treatment of central serous chorioretinopathy.

Authors:  E Moisseiev; A J Holmes; A Moshiri; L S Morse
Journal:  Eye (Lond)       Date:  2016-04-08       Impact factor: 3.775

6.  The time of resolution and the rate of recurrence in acute central serous chorioretinopathy following spontaneous resolution and low-fluence photodynamic therapy: a case-control study.

Authors:  A Ozkaya; Z Alkin; M Ozveren; A T Yazici; M Taskapili
Journal:  Eye (Lond)       Date:  2016-04-22       Impact factor: 3.775

7.  Selective retina therapy with automatic real-time feedback-controlled dosimetry for chronic central serous chorioretinopathy in Korean patients.

Authors:  Young Gun Park; Seungbum Kang; Minhee Kim; Nari Yoo; Young Jung Roh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-04-18       Impact factor: 3.117

8.  Long-term chorioretinal changes after photodynamic therapy for chronic central serous chorioretinopathy.

Authors:  Helena Vasconcelos; Inês Marques; A Rita Santos; Pedro Melo; Isabel Pires; João Figueira; José Faria de Abreu; M Luz Cachulo; Rufino Silva
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-02-07       Impact factor: 3.117

9.  One-year results of reduced fluence photodynamic therapy for central serous chorioretinopathy: the outer nuclear layer thickness is associated with visual prognosis.

Authors:  Yasuhiro Ohkuma; Takaaki Hayashi; Tsutomu Sakai; Akira Watanabe; Hiroshi Tsuneoka
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-03-02       Impact factor: 3.117

10.  Severe visual loss secondary to central serous chorioretinopathy following prolonged immune suppression with oral prednisolone.

Authors:  A Harikrishnan; K Anderson; S Patra
Journal:  JRSM Short Rep       Date:  2010-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.